Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HURA TuHURA Biosciences	$2.23 -5.1%	$3.35	$1.80 ▼ $7.93	$102.65M	0.23	243,989 shs	327,129 shs
KALA KALA BIO	$4.70 +17.5%	$3.82	$2.92 ▼ $11.20	$25.81M	-1.98	96,490 shs	208,044 shs
LRMR Larimar Therapeutics	$3.25 +8.7%	$2.37	$1.61 ▼ $11.20	$191.44M	0.79	841,208 shs	2.03 million shs
NLTX Neoleukin Therapeutics	$17.20 -0.1%	$17.03	$2.03 ▼ $14.36	$161.65M	1.11	50,104 shs	238,965 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HURA TuHURA Biosciences	-7.11%	-4.08%	-16.96%	-33.99%	+234,999,900.00%
KALA KALA BIO	-0.50%	-4.31%	-0.99%	-39.12%	-18.37%
LRMR Larimar Therapeutics	+23.55%	+11.15%	+59.89%	+32.89%	-58.98%
NLTX Neoleukin Therapeutics	-3.04%	-9.23%	-0.35%	+23.35%	-44.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HURA TuHURA Biosciences	1.4375 of 5 stars	3.7	0.0	0.0	0.0	1.9	0.0	0.0
KALA KALA BIO	2.4764 of 5 stars	3.5	1.0	0.0	4.4	0.0	0.8	0.6
LRMR Larimar Therapeutics	1.8518 of 5 stars	3.6	3.0	0.0	0.0	0.6	1.7	0.0
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HURA TuHURA Biosciences	3.40	Buy	$12.67	468.01% Upside
KALA KALA BIO	3.00	Buy	$13.50	187.23% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	469.23% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KALA, LRMR, HURA, and NLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/3/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
3/25/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00 ➝ $26.00
3/25/2025	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
KALA KALA BIO	$3.89M	7.79	N/A	N/A	$2.02 per share	2.33
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	291.69%	122.09%	N/A
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A

Latest KALA, LRMR, HURA, and NLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HURA TuHURA Biosciences	N/A	3.00	3.00
KALA KALA BIO	3.19	1.99	1.99
LRMR Larimar Therapeutics	N/A	7.48	7.48
NLTX Neoleukin Therapeutics	N/A	15.33	15.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HURA TuHURA Biosciences	0.62%
KALA KALA BIO	24.61%
LRMR Larimar Therapeutics	91.92%
NLTX Neoleukin Therapeutics	52.37%

Insider Ownership

Company	Insider Ownership
HURA TuHURA Biosciences	0.20%
KALA KALA BIO	8.32%
LRMR Larimar Therapeutics	4.50%
NLTX Neoleukin Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HURA TuHURA Biosciences	N/A	43.68 million	43.59 million	N/A
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data

KALA, LRMR, HURA, and NLTX Headlines

Recent News About These Companies

Neoleukin Therapeutics (NASDAQ:NLTX) Stock Price Down 4.8% - Time to Sell?

June 10, 2025 | marketbeat.com

(NGNE) Proactive Strategies

October 18, 2024 | news.stocktradersdaily.comN

Neurogene concludes merger deal with Neoleukin Therapeutics

December 20, 2023 | pharmaceutical-technology.comP

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

December 20, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

December 14, 2023 | finance.yahoo.com

Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates

December 4, 2023 | benzinga.com

Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…

October 5, 2023 | markets.businessinsider.com

Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 26, 2023 | finanznachrichten.de

Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%

September 26, 2023 | dhakatribune.comD

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Investing in Neoleukin Therapeutics Inc. [NLTX]: What You Must Know

August 21, 2023 | knoxdaily.comK

Neoleukin Therapeutics Recent Insider Activity

August 18, 2023 | benzinga.com

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

August 18, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

August 1, 2023 | markets.businessinsider.com

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc

July 28, 2023 | finance.yahoo.com

Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm

July 26, 2023 | benzinga.com

Analysts review Neoleukin Therapeutics Inc.’s rating

July 26, 2023 | knoxdaily.comK

ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF

July 24, 2023 | kentuckytoday.comK

Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics

July 24, 2023 | 247wallst.com

An Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growth

July 19, 2023 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA, LRMR, HURA, and NLTX Company Descriptions

TuHURA Biosciences NASDAQ:HURA

$2.23 -0.12 (-5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 +0.03 (+1.35%)

As of 07:55 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

KALA BIO NASDAQ:KALA

$4.70 +0.70 (+17.50%)

Closing price 04:00 PM Eastern

Extended Trading

$4.83 +0.13 (+2.85%)

As of 07:56 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.25 +0.26 (+8.70%)

Closing price 04:00 PM Eastern

Extended Trading

$3.28 +0.03 (+0.89%)

As of 07:57 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Neoleukin Therapeutics NASDAQ:NLTX

$17.20 -0.02 (-0.12%)

As of 06/24/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time